|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OSGEP |
Gene summary for OSGEP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OSGEP | Gene ID | 55644 |
| Gene name | O-sialoglycoprotein endopeptidase | |
| Gene Alias | GAMOS3 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0002949 | UniProtAcc | Q9NPF4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55644 | OSGEP | LZE4T | Human | Esophagus | ESCC | 1.56e-12 | 3.40e-01 | 0.0811 |
| 55644 | OSGEP | LZE5T | Human | Esophagus | ESCC | 5.79e-09 | 4.72e-01 | 0.0514 |
| 55644 | OSGEP | LZE7T | Human | Esophagus | ESCC | 2.45e-03 | 1.82e-01 | 0.0667 |
| 55644 | OSGEP | LZE8T | Human | Esophagus | ESCC | 8.87e-10 | 3.67e-01 | 0.067 |
| 55644 | OSGEP | LZE20T | Human | Esophagus | ESCC | 3.59e-07 | 3.14e-01 | 0.0662 |
| 55644 | OSGEP | LZE21D1 | Human | Esophagus | HGIN | 1.62e-04 | 2.96e-01 | 0.0632 |
| 55644 | OSGEP | LZE24T | Human | Esophagus | ESCC | 1.76e-15 | 4.01e-01 | 0.0596 |
| 55644 | OSGEP | LZE6T | Human | Esophagus | ESCC | 1.39e-03 | 1.69e-01 | 0.0845 |
| 55644 | OSGEP | P1T-E | Human | Esophagus | ESCC | 2.68e-14 | 3.81e-01 | 0.0875 |
| 55644 | OSGEP | P2T-E | Human | Esophagus | ESCC | 1.56e-24 | 3.96e-01 | 0.1177 |
| 55644 | OSGEP | P4T-E | Human | Esophagus | ESCC | 8.84e-37 | 7.95e-01 | 0.1323 |
| 55644 | OSGEP | P5T-E | Human | Esophagus | ESCC | 1.16e-20 | 3.45e-01 | 0.1327 |
| 55644 | OSGEP | P8T-E | Human | Esophagus | ESCC | 4.11e-23 | 2.99e-01 | 0.0889 |
| 55644 | OSGEP | P9T-E | Human | Esophagus | ESCC | 8.62e-13 | 2.11e-01 | 0.1131 |
| 55644 | OSGEP | P10T-E | Human | Esophagus | ESCC | 2.86e-31 | 5.15e-01 | 0.116 |
| 55644 | OSGEP | P11T-E | Human | Esophagus | ESCC | 2.52e-13 | 3.35e-01 | 0.1426 |
| 55644 | OSGEP | P12T-E | Human | Esophagus | ESCC | 4.61e-38 | 7.25e-01 | 0.1122 |
| 55644 | OSGEP | P15T-E | Human | Esophagus | ESCC | 7.33e-31 | 7.19e-01 | 0.1149 |
| 55644 | OSGEP | P16T-E | Human | Esophagus | ESCC | 4.09e-20 | 3.45e-01 | 0.1153 |
| 55644 | OSGEP | P17T-E | Human | Esophagus | ESCC | 3.55e-09 | 4.42e-01 | 0.1278 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447010 | Esophagus | HGIN | ncRNA processing | 97/2587 | 395/18723 | 5.92e-09 | 3.90e-07 | 97 |
| GO:00346606 | Esophagus | HGIN | ncRNA metabolic process | 104/2587 | 485/18723 | 2.26e-06 | 8.23e-05 | 104 |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:00080333 | Esophagus | ESCC | tRNA processing | 92/8552 | 127/18723 | 7.83e-10 | 1.93e-08 | 92 |
| GO:00063992 | Esophagus | ESCC | tRNA metabolic process | 122/8552 | 179/18723 | 9.03e-10 | 2.19e-08 | 122 |
| GO:00094512 | Esophagus | ESCC | RNA modification | 114/8552 | 167/18723 | 2.76e-09 | 6.04e-08 | 114 |
| GO:00064002 | Esophagus | ESCC | tRNA modification | 62/8552 | 90/18723 | 7.02e-06 | 7.04e-05 | 62 |
| GO:00344701 | Liver | Cirrhotic | ncRNA processing | 158/4634 | 395/18723 | 1.09e-11 | 6.96e-10 | 158 |
| GO:00346603 | Liver | Cirrhotic | ncRNA metabolic process | 173/4634 | 485/18723 | 3.64e-08 | 1.21e-06 | 173 |
| GO:00344702 | Liver | HCC | ncRNA processing | 293/7958 | 395/18723 | 4.26e-38 | 6.76e-35 | 293 |
| GO:00346601 | Liver | HCC | ncRNA metabolic process | 332/7958 | 485/18723 | 1.48e-31 | 7.80e-29 | 332 |
| GO:0008033 | Liver | HCC | tRNA processing | 87/7958 | 127/18723 | 2.66e-09 | 7.23e-08 | 87 |
| GO:0006399 | Liver | HCC | tRNA metabolic process | 108/7958 | 179/18723 | 1.07e-06 | 1.59e-05 | 108 |
| GO:0009451 | Liver | HCC | RNA modification | 101/7958 | 167/18723 | 2.02e-06 | 2.78e-05 | 101 |
| GO:0006400 | Liver | HCC | tRNA modification | 60/7958 | 90/18723 | 3.09e-06 | 4.09e-05 | 60 |
| GO:00344709 | Oral cavity | OSCC | ncRNA processing | 263/7305 | 395/18723 | 4.38e-29 | 2.78e-26 | 263 |
| GO:00346605 | Oral cavity | OSCC | ncRNA metabolic process | 296/7305 | 485/18723 | 2.94e-23 | 6.65e-21 | 296 |
| GO:00080332 | Oral cavity | OSCC | tRNA processing | 78/7305 | 127/18723 | 2.56e-07 | 4.00e-06 | 78 |
| GO:00063991 | Oral cavity | OSCC | tRNA metabolic process | 101/7305 | 179/18723 | 1.65e-06 | 2.15e-05 | 101 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OSGEP | SNV | Missense_Mutation | c.679N>A | p.Glu227Lys | p.E227K | Q9NPF4 | protein_coding | deleterious(0.02) | possibly_damaging(0.663) | TCGA-LP-A4AU-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
| OSGEP | SNV | Missense_Mutation | c.890C>A | p.Ala297Glu | p.A297E | Q9NPF4 | protein_coding | deleterious(0) | probably_damaging(0.961) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| OSGEP | SNV | Missense_Mutation | rs375098598 | c.890N>T | p.Ala297Val | p.A297V | Q9NPF4 | protein_coding | tolerated(0.2) | benign(0.033) | TCGA-AA-3489-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| OSGEP | SNV | Missense_Mutation | rs374503423 | c.922N>T | p.Arg308Trp | p.R308W | Q9NPF4 | protein_coding | deleterious(0) | benign(0.339) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
| OSGEP | SNV | Missense_Mutation | rs374503423 | c.922C>T | p.Arg308Trp | p.R308W | Q9NPF4 | protein_coding | deleterious(0) | benign(0.339) | TCGA-EI-6506-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSGEP | SNV | Missense_Mutation | rs755083336 | c.460G>A | p.Asp154Asn | p.D154N | Q9NPF4 | protein_coding | deleterious(0.01) | possibly_damaging(0.728) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| OSGEP | SNV | Missense_Mutation | novel | c.566A>C | p.Lys189Thr | p.K189T | Q9NPF4 | protein_coding | tolerated(0.06) | benign(0.081) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| OSGEP | SNV | Missense_Mutation | novel | c.550G>T | p.Ala184Ser | p.A184S | Q9NPF4 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| OSGEP | SNV | Missense_Mutation | novel | c.115G>A | p.Gly39Arg | p.G39R | Q9NPF4 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| OSGEP | SNV | Missense_Mutation | rs748651554 | c.458N>C | p.Ile153Thr | p.I153T | Q9NPF4 | protein_coding | deleterious(0) | possibly_damaging(0.876) | TCGA-A5-A0GW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |